Jupiter Neurosciences buys U.S. rights to psychedelic asset ALA-002

Jupiter Neurosciences said July 22 it signed a definitive license deal for exclusive U.S. rights to ALA-002, a patented MDMA-based drug candidate from PharmAla Biotech Holdings. The agreement could be worth up to $100 million and gives Jupiter a second clinical-stage CNS program as it pushes its Parkinson’s pipeline forward.

Why it matters: - Jupiter Neurosciences is moving from a single-program company to a dual clinical-stage central nervous system developer. - The deal adds a second development asset alongside Jupiter’s Parkinson’s program and gives the company perpetual exclusive U.S. rights to ALA-002. - The agreement could expand Jupiter’s long-term commercial opportunity in the United States if ALA-002 advances through development and approval.

What happened: - Jupiter Neurosciences announced a definitive license agreement with PharmAla Biotech Holdings for ALA-002. - The announcement came July 22, 2026. - The rights are perpetual and exclusive in the United States. - The transaction has a potential value of up to $100 million, including milestone payments, and excludes ongoing royalties.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in Jupiter common stock subject to a 120-day lock-up. - Jupiter owes a $3.3 million development milestone if ALA-002 reaches Phase 3 first patient in. - Jupiter owes a $20 million regulatory milestone upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when U.S. net sales reach $333 million, $1 billion and $2 billion. - Jupiter will also pay a 3% royalty on net sales starting after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation with FDA Novel Chemical Entity designation. - FDA NCE designation can provide five-year data exclusivity upon approval. - Jupiter said ALA-002 was engineered to improve cardiovascular safety and reduce abuse liability while preserving the pro-social and therapeutic properties associated with MDMA-assisted psychotherapy. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - Jupiter said PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - Jupiter’s lead program, JOTROL, is a proprietary enhanced-bioavailability resveratrol formulation currently in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement. - Jupiter is a B2i Digital Featured Company, and the company profile is available here. - The company also pointed investors to its website.

Between the lines: - Jupiter is pairing a Parkinson’s program with a psychedelic medicine asset, giving the company two shots at clinical catalysts. - Management described the move as portfolio diversification across a natural resveratrol program and a Novel Chemical Entity. - The company is also leaning on a more favorable U.S. policy backdrop for investigational psychedelic therapies. - Jupiter pointed to an April 18, 2026 executive order that it said directs the FDA and DEA to expand access to investigational psychedelic treatments. - The company said the order includes a Right to Try pathway, expedited FDA review vouchers for some psychedelic drugs with Breakthrough Therapy designation and $50 million in ARPA-H funding. - Those policy changes are potential tailwinds, not guarantees, because ALA-002 still faces clinical, regulatory and financing risk.

What's next: - Jupiter said its focus is now on clinical execution, capital allocation and moving both programs toward value-creating milestones. - The company will need to advance ALA-002 through development, secure regulatory review and eventually reach commercialization to realize the full deal value. - Management said the next 12 months will be transformative for Jupiter.

The bottom line: - Jupiter is betting that exclusive U.S. rights to ALA-002 can turn it into a broader CNS company with multiple clinical catalysts and a longer runway for growth.